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ABSTRACT 
Objectives To evaluate whether elderly people and women are adequately represented in randomized 
controlled trials (RCT) in rheumatoid arthritis (RA) and osteoarthritis (OA).  
Methods Four systematic searches in MEDLINE yielded RCT in RA and OA on any intervention published 
in 2016 and 2017 and population-based studies (PBS) in RA and OA published between 2013 and 2017. 
Random effects meta-analyses estimated the pooled proportion of elderly people (defined as being 
≥65 years old), the mean age, its standard deviation (SD), and the proportion of women stratified by 
disease (RA and OA) and study type (RCT and PBS). Stratified estimates were subsequently compared.  
Results 265 RCT comprising 51,240 participants and 53 PBS comprising 523,630 participants were 
included. In both RA and OA, RCT included lower proportions of elderly people than PBS: RA –0.18 
(95% confidence interval –0.22 to –0.13); OA –0.20 (–0.30 to –0.09); had lower mean ages: RA –5.2 
years (–6.8 to –3.5); OA –4.7 years (–7.5 to –2.0); and smaller SD: RA –1.9 years (–2.6 to –1.3); OA –2.7 
years (–4.2 to –1.2); (all comparisons: p ≤ 0.001). Proportions of women were comparable in RCT 
compared to PBS in both RA and OA.  
Conclusions While women are adequately represented in RA and OA trials, the elderly are 
underrepresented, probably limiting applicability of current evidence to this growing subgroup. It is 
urgent to improve the inclusion of elderly people in clinical trials and study age as a determinant for 
outcome. 
Systematic Review Registration PROSPERO (CRD42018085409) 
Keywords Applicability, Generalizability, Elderly, Women, Rheumatoid Arthritis, Osteoarthritis
 
Abbreviations 
RCT – Randomized controlled trial; RA – Rheumatoid arthritis; OA – Osteoarthritis; PBS – Population-based study;  
SD – Standard deviation 
INTRODUCTION 
Randomized controlled trials (RCT) shape the evidence base and are generally considered the gold 
standard in clinical research. However, their results are not necessarily applicable to the whole 
population suffering from the diseases under investigation.[1] Applicability (sometimes called 
generalizability or external validity) can be defined the extent to which ‘available research evidence 
can be directly utilized to answer the healthcare questions at hand’.[1, 2] It is a key factor in the 
translation of clinical research to the real world.[1] There are several characteristics in which trial 
populations may differ from real-world patients and which therefore affect trial result applicability, 
e.g., sex, age, and comorbidities.[1] 
 
Despite the considerable rise in numbers of elderly people – ‘elderly’ commonly defined as aged 65 
years or more – in countries all over the world,[3] this group is underrepresented in clinical trials across 
various medical fields.[4-11] Such underrepresentation bears considerable risks as elderly differ from 
younger people in several aspects, including pharmacodynamics and pharmacokinetics, comorbidity, 
polypharmacy, and physical performance.[12, 13] All of these may affect the potential for benefit and 
usually increase the risk of harm. Women are underrepresented, too, with similar implications.[1, 7, 
14-16]  
 
Empirical evidence on the representation of elderly people and women in rheumatologic clinical trials 
is lacking. Rheumatoid arthritis (RA) and osteoarthritis (OA) are two of the most common chronic 
rheumatic diseases and major contributors to global disability.[17-22] Both tend to occur 
predominantly in elderly people – and mostly in women.[17-23] We therefore investigated whether 
RCT reflect these tendencies, possess similar characteristics in age distribution measures and include 
proportions of elderly people and women comparable to real-world data obtained by population-
based studies (PBS) including registries. Additionally, we assessed whether there are associations 
between proportions of elderly people and industry funding and different types of intervention. 
 
METHODS 
This study is part of the GLORIA project and trial (Glucocorticoid low-dose outcome in rheumatoid 
arthritis study; http://www.gloriatrial.org/; registered on http://clinicaltrials.gov/; identifier 
NCT02585258).[24] It conforms to the PRISMA (for systematic reviews of interventional studies) and 
MOOSE (for systematic reviews of observational studies) guidelines (see supplementary file for 
research checklists).[25, 26] The prespecified protocol (see supplementary file) was preregistered with 
the protocol registry for systematic reviews, PROSPERO (CRD42018085409).
 Search strategy  
Using the biomedical database MEDLINE (via PubMed), we conducted separate searches for RCT and 
PBS in RA and OA through 31 December 2017. We limited the search for RCT to trials published from 
1 January 2016, whereas our search for PBS began with 1 January 2013 to ensure sufficient real-world 
data. Additionally, we performed a hand search for relevant publications including a scan of the 
references of major guidelines and reviews of RA and OA. We decided a priori that we would not 
attempt to contact study authors or include unpublished studies. For exact search strings, which we 




All studies (both RCT and PBS) had to report the mean or median age at baseline of all included 
patients/populations. Corresponding to GLORIA collaborators, we excluded publications in languages 
other than English, French, Spanish, German, Italian, Hungarian, Portuguese, Dutch, Slovakian, and 
Romanian. We defined PBS as observational studies fulfilling one of the following criteria: study 
objective being the determination of RA or OA prevalence in the general population; studies with other 
objectives, but undertaken in prevalent RA or OA populations without apparent selection mechanisms 
as to age or gender; or studies in ongoing RA or OA registries.[27] For additional specifications please 
refer to our study protocol. 
 
Two reviewers (AP and TB) independently selected the studies. After removing duplicates, they 
screened the articles by title and abstract, and assessed potentially eligible articles in full-text. They 
achieved consensus by discussion when necessary.  
 
Data extraction  
We extracted the data using predefined data extraction sheets which we derived from the Cochrane 
Collaboration’s recommendations for data extraction and modified for our purposes.[28] We 
dichotomized information on funding into any industry funding and no industry funding, and 
categorized treatment modalities into pharmacological, surgical, physical/physiotherapeutic, and 
psychological. 
 
Risk of bias 
Two reviewers (AP and TB) independently assessed risk of bias of the included PBS using the newest 
version of the Joanna Briggs Institute Critical Appraisal Checklist for Prevalence Studies.[29, 30] 
Discussion resolved rating discrepancies. Regarding RCT, our sole outcomes were baseline 
 characteristics, so we considered quality appraisal not to be necessary. We did not assess risk of bias 
across studies, e.g., publication bias,[25] since, in our opinion, there is no reason to believe that any of 
our study variables makes studies more or less likely to get published. 
 
Data synthesis 
We used R (R Foundation for Statistical Computing, Vienna, Austria) with packages meta and metafor 
and Microsoft Excel 2016 (Microsoft Corporation, Redmond, WA, USA) software for data extraction, 
management, and analysis. The format of reporting results conforms to guidelines recently proposed 
by one of us.[31] 
 
We either extracted the proportion of elderly participants from the research manuscript or estimated 
it. In the latter case, we estimated the proportion utilizing an established method under assumption 
that age is distributed normally, but with truncation as trials employ upper and/or lower age limits as 
exclusion criteria.[8, 9, 32] The model considers studies to be either singly (assuming a lower age limit 
of 18 years if not reported otherwise) or doubly truncated.  
 
We conducted restricted maximum likelihood random effects meta-analyses on each of our four 
outcomes: the proportion of elderly people (i.e., aged ≥65 years), the mean age, its SD (as a measure 
of dispersion), and the proportion of women (all performed separately for RCT and PBS and stratified 
by disease). We subsequently compared the results and tested the differences for statistical 
significance with two-sample Z-tests.[33] We evaluated heterogeneity with Cochran’s Q-statistic and 
present it as an I2-value, which estimates the total percentage of variance across studies due to 
heterogeneity rather than statistical error.[28, 34] In RCT, we additionally assessed whether 
representation of elderly people differed across funding and intervention types through meta-
regression analysis including a factor for funding or intervention and testing for moderators with Wald-
type tests.[35] We set the two-sided significance level α at .05. For additional specifications concerning 




Our database search yielded 3,065 results (Figure 1). We identified 11 additional articles by hand 
search. Of these 3,076 publications, 265 RCT and 53 PBS were finally deemed eligible (see 
supplementary file for a list of all included studies).   
 
 
 Study characteristics 
RCT included 51,240 patients (30,410 RA and 20,830 OA patients; Table 1). The majority of included 
RCT originated from Europe and Asia, although most RA RCT were not limited to one region. In RA RCT, 
industry funding was more prominent than in OA RCT. None of the studies that explicitly excluded 
elderly patients provided a reason for doing so. Seven RCT (3%) reported the proportion of elderly 
participants, and five RCT (2%), all on OA, assessed the influence of participant age on outcomes. 
 
PBS included 523,630 patients (449,329 RA patients and 74,301 OA patients). Just like RCT, most PBS 
were conducted in Europe and Asia. No PBS reported the proportion of elderly participants. 
 
Risk of bias assessments are presented in the supplementary file. In 38% of PBS, authors did not report 
the number of people willing or refusing to participate, and in 34% it was unclear whether data analysis 
was performed with sufficient coverage of the identified sample. Other potential sources of bias 
include ambiguity regarding disease identification methods (30%) and execution of these (21%). The 
sample size was considered low in 25% of PBS. Overall, studies in healthcare and insurance databases 
had the lowest percentage of questions answered “no” (0% of questions). 
 
Comparison of RCT and PBS 
In both RA and OA, RCT included significantly fewer elderly people than did PBS (Figure 2): RA –0.18 
(95% confidence interval –0.22 to –0.13); OA –0.20 (–0.30 to –0.09); and had significantly lower mean 
ages: RA –5.2 years (–6.8 to –3.5); OA –4.7 years (–7.5 to –2.0). RCT also had smaller SD: RA –1.9 years  
(–2.6 to –1.3); OA –2.7 years (–4.2 to –1.2); (all comparisons p≤0.001). In both RA and OA, RCT included 
similar proportions of women compared to PBS: RA 0.02 (–0.01 to 0.05); OA –0.04 (–0.10 to 0.03). 
Heterogeneity was considerable in all meta-analyses with I² values between 96% and 100%. Individual 
meta-analyses are presented in the supplementary file. 
 
Stratified analyses 
Funding source did not influence the deficit of elderly in RCT (RA, p = 0.82; OA, p = 0.26; Table 2). Type 
of intervention did influence the deficit, but only in RA (RA, p = 0.02; OA, p = 0.60). 
 
DISCUSSION 
We found the elderly to be underrepresented in RA and OA trials; mean ages and the variation in age 
(SD) were lower in RCT than in PBS. RCT included proportions of women comparable to real-world 
 settings. While the proportion of included elderly patients showed no association with industry 
funding, it differed in RA RCT but not in OA RCT depending on the intervention. 
 
Intense and successful research in rheumatology has led to crucial discoveries in disease mechanisms 
and both diagnostic and therapeutic management over the last two decades. While all this research 
surely has and will continue to benefit most patients, our study suggests applicability to the large 
subgroup of elderly patients may be limited. 
 
Underrepresentation of the elderly in medical science is not a new phenomenon.[10] Since its 
documentation in cardiology in the 1990s,[7] it has been confirmed in renal, neurological, and 
oncological diseases, in diabetes, and in surgical procedures (see supplementary file for a list of studies 
on this subject). Current guidelines still widely rely on trials lacking applicability to elderly patients.[11, 
16]  
 
Various national and international institutions have acknowledged this problem and have undertaken 
efforts to tackle this issue. The U.S. food and drug administration (FDA) requires drug sponsors to 
report trial data by age,[36, 37] but low numbers of elderly in clinical trials diminish the statistical 
power to detect significant differences between them and their younger counterparts in both efficacy 
and safety.[37, 38] The International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use and the European Forum for Good Clinical Practice 
have issued guidance for research in the geriatric population.[38, 39] It has been demanded repeatedly 
that institutional review boards and journals pay attention to whether applicability of trial results 
concerning age is assured.[7, 40] All the same, elderly people still seem to be underrepresented in 
clinical trials. 
 
In RA and OA trials, two publications suggested underrepresentation of the elderly: In RA, patients in 
RCT of etanercept, rituximab, and tocilizumab were younger than those enrolled in observational 
studies on these agents.[41] In OA, 38% of trials published before 2007 did not have patients above 
the age of 80 years, and 11% explicitly excluded elderly patients.[42] In our study this proportion was 
more pronounced at 36%. 
 
It remains unclear why the elderly are actively excluded by trials installing upper age limits. No trial in 
our study justified doing so, although justification of exclusion criteria has been demanded 
repeatedly.[5] In trials, investigators generally aim for homogeneous study samples and might fear 
higher rates of (serious) adverse events and drop-outs in aged people.[4, 43, 44] Other mechanisms 
 that keep the elderly from participating are exclusion criteria related to age such as comorbidities, 
strict organ function criteria, or performance status.[45, 46] Physician- and patient-level factors that 
add to this are, amongst others, physicians being reluctant to include elderly people due to fear of 
increased toxicity, and elderly people themselves having difficulties judging benefits and risks.[45-47]  
 
We did not find a statistically significant association between industry funding and the proportion of 
elderly people. Previous studies have come to varying results, with industry funding being associated 
with higher (in heart failure trials), lower (across trials of all specialties), and no different rates (in trials 
on statins, non-steroidal anti-inflammatory drugs, and type 2 diabetes mellitus) of explicit exclusion of 
elderly people.[4, 5, 48, 49] The lack of influence of type of intervention in OA trials (in contrast to RA 
trials) is surprising, since adequate interventions (e.g., endoprosthetic surgery) depend on the severity 
of the disease (e.g., late-stage OA) and could therefore be associated with age. To sum up, evidence is 
ambiguous, but associations in both respects might vary between diseases.  
 
Numerous attempts have been made to analyze how age affects trial outcomes, and studies doing so 
have yielded quite heterogeneous results. As one example, thrombolytic and interventional therapy is 
associated with higher mortality in older patients with myocardial infarction, while the elderly had 
similar response and survival rates in trials on lung and breast cancer.[50-53] Recent research suggests 
lower response rates to biologicals in elderly RA patients and a diminished benefit-to-risk ratio.[54-56] 
Of all 265 RCT included in our study, only five analyzed age as a determinant for outcome. Their results 
were conflicting: In two studies, older participants profited less or had worse outcomes than younger 
ones,[57, 58] but experienced a more pronounced treatment effect in another.[59]  
 
In contrast to the past and the present in other medical specialties,[7, 14-16] we did not find women 
to be underrepresented. In fact, women make up the majority of patients included in current RA and 
OA clinical trials. Generally, this is consistent with the distribution of RA and OA in men and women. 
With increasing age, however, gender disparities in both diseases decrease.[60, 61] Thus, it should be 
underlined that current evidence is especially sparse regarding elderly men.  
 
Both efficacy and safety data must be interpreted with caution if they stem from study populations 
which differ from general diseased populations in age or sex (or disease duration, or disease severity, 
etc.). In the past, young Caucasian males were usually considered the ideal study subjects, and 
pharmacodynamic and -kinetic differences in other subpopulations were paid little attention, as was 
the case with differing comorbidities or drug interactions (think of polypharmacy in the elderly).[10] 
Drugs were approved without sufficient study in elderly people, non-whites, or women.[10]  
  
An infamous example of this phenomenon is benoxaprofen, a drug introduced in the 1980s to treat 
arthritic conditions.[62] Benoxaprofen had previously been studied in large clinical trials. However, its 
licenses were suspended only two years after launch because of unacceptable rates of (serious) 
adverse events in ‘real-world’ patients, including deaths – mostly in the elderly, who had been studied 
very little before.[62] Researchers later found tremendous pharmacological differences between the 
elderly and younger (or – as the researchers put it – ‘normal’) patients.[63] 
 
Researchers should investigate the effect of age and other covariates such as sex on outcomes 
routinely on trial-level data. However, this is only useful when adequate numbers of, e.g., elderly 
people are included in clinical trials.[37, 38] The current meta-analysis was performed under the 
umbrella of the GLORIA project, which also includes a trial focusing specifically on RA patients aged 65 
or over.[24] While studies aimed at younger populations might measure outcomes and define 
endpoints that are less relevant to elderly people, performing trials focused on the elderly is an option. 
This option takes into consideration that some outcomes are particularly valuable for older 
patients.[64-66] Such relevant outcomes include functional ones (e.g., quality of life) instead of solely 
disease-specific ones.[64-66] Factors that impede inclusion and retention of the elderly (at trial-, 
physician- and patient-level) have been identified and should be countered.[45-47, 67-70] Another 
option is to replace the traditional explanatory RCT by a pragmatic design: for example, the GLORIA 
trial has very ‘relaxed’ eligibility criteria, uses routinely collected data where possible, and takes place 
in the routine clinical setting.[71] Yet another option is to construct and conduct RCT on the foundation 
of ongoing observational studies. These so-called registry-based RCT usually cover real-world settings 
and go with higher applicability as well.[72] 
 
To our knowledge, this is the first study to prove and quantify underrepresentation of elderly people 
in rheumatology by comparing RCT and PBS. Strengths include the high number of studies and 
participants, a systematic literature search not limited to the English language, and protocolized 
execution. Study selection and risk of bias assessment were performed independently by two authors 
to reduce the risk of systematic bias. We excluded RCT that only presented baseline characteristics 
from study finishers, so our results should not be affected by the possibility that older patients may be 
prone to dropping out. 
 
This study also has limitations. We have restricted our search to MEDLINE, but it is unlikely that our 
results would differ by including trials indexed elsewhere only. Furthermore, with our search restricted 
to RCT published within the last two years, our analyses reflect only the current situation, but we feel 
 that is most relevant. Finally, the assessment of the ‘real’ prevalence is dependent on the quality of 
population-based evidence, and some studies had flaws. Nonetheless, we are convinced these flaws 
do not cast doubt on our overall results.  
 
We did encounter considerable heterogeneity in all meta-analyses. Some heterogeneity will be due to 
our ‘relaxed’ eligibility criteria, which led to inclusion of a variety of study types and interventions. In 
RCT, heterogeneity may be caused by studies being aimed at or explicitly excluding elderly people, 
women, or patients in a certain disease stage. Regarding both RCT and PBS, heterogeneity could also 
be explained by varying demographics across different regions. Overall, though, only three RA PBS and 
one OA PBS included proportions of elderly people that were smaller than pooled RCT estimates. 
Accordingly – since meta-analytical estimates were consistent — we did not perform additional 
sensitivity analyses.[34] Finally, we had to estimate proportions of elderly people in the majority of 
RCT and PBS. However, our method to do so is established and has been applied repeatedly.[8, 9] 
 
CONCLUSIONS 
Our study proves that elderly people, but not women, are significantly underrepresented in 
randomized clinical trials on rheumatoid arthritis and osteoarthritis, raising serious concerns about 
applicability of their results. It is urgent to improve the inclusion of elderly people in clinical trials and 
to study age and sex as a determinant for outcome.   
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(409 - 8,998) 
696  
(161 - 11,111) 
212  
(72 - 386) 
81  
(48 - 164) 
Numbers are percentages if not stated otherwise. PBS, population-based studies, RCT, randomized 
controlled trials, RA, rheumatoid arthritis, OA, osteoarthritis, and NA, not applicable. aPercentages are 
based on all pharmacological studies in the respective disease. bPercentages are based on all studies on 
biologic agents in the respective disease. cMultiple nominations per study possible. dE.g., no funding and 
conflicts of interest statement. eMedian (IQR). 
 Table 2. Proportions of elderly people in randomized controlled trials stratified by funding and intervention. 
 RA OA 
Funding        
No industry funding 0.13 0.17 0.20 0.42 0.47 0.52 
Any industry funding 0.14 0.16 0.18 0.33 0.42 0.50 
Intervention       
Psychological 0.19 0.29 0.39 0.29 0.50 0.72 
Surgical  -  0.40 0.49 0.58 
Physical/physiotherapeutic 0.11 0.18 0.25 0.39 0.46 0.54 
Pharmacological 0.14 0.16 0.18 0.36 0.44 0.53 
Other 0.00 0.09 0.18 0.29 0.39 0.49 
Numbers are the proportion of elderly people surrounded by 95% 







Figure 1. Search flow of population-based studies (PBS) and randomized controlled trials (RCT) in rheumatoid 
arthritis (RA) and osteoarthritis (OA). Database searches were carried out on January 19, 2018. 
  
Figure 2. Meta-analyses’ estimates of population-based studies (PBS) and randomized controlled trials (RCT) in 
rheumatoid arthritis (RA) and osteoarthritis (OA) for the proportion of elderly people, mean age, standard 
deviation of age, and the proportion of women. CI, confidence interval. 
